These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30187159)

  • 21. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
    Zivadinov R; Uher T; Hagemeier J; Vaneckova M; Ramasamy DP; Tyblova M; Bergsland N; Seidl Z; Dwyer MG; Krasensky J; Havrdova E; Horakova D
    Mult Scler; 2016 Nov; 22(13):1709-1718. PubMed ID: 26883943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
    De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
    Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization.
    De Stefano N; Giorgio A; Gentile G; Stromillo ML; Cortese R; Gasperini C; Visconti A; Sormani MP; Battaglini M
    Ann Clin Transl Neurol; 2021 Mar; 8(3):623-630. PubMed ID: 33534940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal associations between brain structural changes and fatigue in early MS.
    Nourbakhsh B; Azevedo C; Nunan-Saah J; Maghzi AH; Spain R; Pelletier D; Waubant E
    Mult Scler Relat Disord; 2016 Jan; 5():29-33. PubMed ID: 26856940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Lanzillo R; Quarantelli M; Pozzilli C; Trojano M; Amato MP; Marrosu MG; Francia A; Florio C; Orefice G; Tedeschi G; Bellantonio P; Annunziata P; Grimaldi LM; Comerci M; Brunetti A; Bonavita V; Alfano B; Marini S; Brescia Morra V;
    Mult Scler; 2016 Aug; 22(9):1163-73. PubMed ID: 26466947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan.
    Hostenbach S; Pauwels A; Michiels V; Raeymaekers H; Van Binst AM; Van Merhaeghen-Wieleman A; Van Schuerbeek P; De Keyser J; D'Haeseleer M
    Trials; 2019 Mar; 20(1):164. PubMed ID: 30871594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study.
    Mostert JP; Admiraal-Behloul F; Hoogduin JM; Luyendijk J; Heersema DJ; van Buchem MA; De Keyser J
    J Neurol Neurosurg Psychiatry; 2008 Sep; 79(9):1027-31. PubMed ID: 18450787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus.
    Sacco R; Bisecco A; Corbo D; Della Corte M; d'Ambrosio A; Docimo R; Gallo A; Esposito F; Esposito S; Cirillo M; Lavorgna L; Tedeschi G; Bonavita S
    J Neurol; 2015 Jul; 262(7):1691-7. PubMed ID: 25957638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Khan O; Shen Y; Caon C; Bao F; Ching W; Reznar M; Buccheister A; Hu J; Latif Z; Tselis A; Lisak R
    Mult Scler; 2005 Dec; 11(6):646-51. PubMed ID: 16320723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis.
    Ma AY; Vitorino RC; Hojjat SP; Mulholland AD; Zhang L; Lee L; Carroll TJ; Cantrell CG; Figley CR; Aviv RI
    Mult Scler; 2017 Dec; 23(14):1884-1892. PubMed ID: 28178867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.
    Obert D; Helms G; Sättler MB; Jung K; Kretzschmar B; Bähr M; Dechent P; Diem R; Hein K
    PLoS One; 2016; 11(9):e0162583. PubMed ID: 27636543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Aging on the Human Brain: A Proton and Phosphorus MR Spectroscopy Study at 3T.
    Schmitz B; Wang X; Barker PB; Pilatus U; Bronzlik P; Dadak M; Kahl KG; Lanfermann H; Ding XQ
    J Neuroimaging; 2018 Jul; 28(4):416-421. PubMed ID: 29630746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Brain metabolism in multiple sclerosis: effects of neurotrophic therapy].
    Pukhov RV; Bisaga GN; Trufanov AG; Efimtsev AIu; Fokin VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):97-104. PubMed ID: 24300822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Untargeted metabolomic analysis of plasma from relapsing-remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain.
    Sylvestre DA; Slupsky CM; Aviv RI; Swardfager W; Taha AY
    Brain Res; 2020 Apr; 1732():146589. PubMed ID: 31816317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
    Pichler A; Khalil M; Langkammer C; Pinter D; Ropele S; Fuchs S; Bachmaier G; Enzinger C; Fazekas F
    Mult Scler; 2019 Jan; 25(1):48-54. PubMed ID: 29027843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural MRI Correlates of Cognitive Event-Related Potentials in Multiple Sclerosis.
    Artemiadis AK; Anagnostouli MC; Zalonis IG; Chairopoulos KG; Triantafyllou NI
    J Clin Neurophysiol; 2018 Sep; 35(5):399-407. PubMed ID: 29649014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.